Private biotechs are operating in a fundraising environment where access to capital is limited. This has led to a spike in shutdowns, restructurings, reductions-in-force, and “strategic alternatives” across the industry that one VC investor recently cited. Smaller and more emerging companies may be wondering how to respond, what nontraditional cash, partnering, and business opportunities exist, and how to continue to access funding. For example, “Should we extend our series A or go for a series B?” The market downturn is likewise impacting tech transfer, company spin-out, and the drug discovery pipeline.

Where are innovation and company creation pausing due to tight cash flows and cautious investors? Listen to a panel of speakers who can comment on these questions and offer insights from investor, university, and biotech perspectives.